SOURCE: Targeted Genetics

September 13, 2007 16:16 ET

Targeted Genetics to Host Conference Call to Discuss the Recombinant DNA Advisory Committee (RAC) Review and the tgAAC94 Clinical Program

SEATTLE, WA--(Marketwire - September 13, 2007) - Targeted Genetics Corporation (NASDAQ: TGEN) will report on the proceedings of the Recombinant DNA Advisory Committee (RAC) and the Company's tgAAC94 clinical program in inflammatory arthritis following the meeting on September 17, 2007.

In addition, management will host a conference call and webcast discussion on Tuesday, September 18, at 10:30 a.m. Eastern Time / 7:30 a.m. Pacific Time. You may access the live webcast via the "Events" section of the Company's website at www.targetedgenetics.com or via telephone at 800-240-2430 (domestic) or 303-262-2131 (international).

The public RAC review is scheduled for Monday, September 17, beginning at 8:00 a.m. EDT. To review the agenda and access the live webcast of the RAC Review, link to: http://www4.od.nih.gov/oba/RAC/meeting.html.

Replay Access

Webcast replay will be available for approximately 30 days at www.targetedgenetics.com; telephone replay will be available approximately one hour following Tuesday's call through 11:59 p.m. PT, Tuesday, October 30, 2007, by calling 800.405.2236 (domestic) or 303.590.3000 (international); pass code 11097397#.

About Targeted Genetics

Targeted Genetics Corporation is a biotechnology company committed to the development of innovative targeted molecular therapies for the prevention and treatment of acquired and inherited diseases with significant unmet medical need. Targeted Genetics' proprietary Adeno-Associated Virus (AAV) technology platform allows it to deliver genes that encode proteins to increase gene function or RNAi to decrease or silence gene function. Targeted Genetics' product development efforts target inflammatory arthritis, AIDS prophylaxis, congestive heart failure and Huntington's disease. To learn more about Targeted Genetics, visit Targeted Genetics' website at www.targetedgenetics.com.

Contact Information

  • Investor and Media Contacts:
    Stacie D. Byars
    Director, Communications
    Targeted Genetics Corporation
    (206) 521-7392

    Lori Murray
    Senior Associate
    WeissComm Partners
    (415) 946-1070